Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2020

Mar 3, 2020

30826_dirs_2020-03-02_0958ca9d-e4c9-424b-858d-89dfd89ceb29.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2020-02-27

Reporting Person: KURIYEL RALF (Senior VP, R&D)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-02-27 Common Stock A 3216 $0.00 Acquired 29529 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-02-27 Stock Option (Right to Buy) $86.10 A 3137 Acquired 2030-02-27 Common Stock (3137) Direct

Footnotes

F1: Mr. Kuriyel was awarded 3,216 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: One third of the stock options will vest and become exercisable annually on February 27, 2021, February 27, 2022 and February 27, 2023.